Cardiff Oncology, Inc. — Director's Dealing 2017

Aug 17, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Trovagene, Inc. (TROV)
CIK: 0001213037
Period of Report: 2017-08-15

Reporting Person: WELCH WILLIAM J (Director, CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-08-15	Common Stock	A	745392	—	Acquired	745392	Direct

Footnotes

F1: Mr. Welch was granted a stock award of 745,392 shares of common stock pursuant to the Trovagene, Inc. 2014 Equity Incentive Plan which vested upon date of grant.